Jinender Kumar

Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study

Franck Morschhauser, Saurabh Dahiya, M. Lia Palomba et al. · Nature Medicine · 2024 · 130 citations · Full text

Medicine, Immunology, Oncology +16

Pharmacist-Provided Medication Therapy Management (MTM) Program Impacts Outcomes for Employees with Diabetes

Sharrel Pinto, Jinender Kumar, G Partha et al. · Population Health Management · 2013 · 82 citations

Pharmacy, Pharmacy Practice, Outcomes Research +16

Improving the economic and humanistic outcomes for diabetic patients: making a case for employer-sponsored medication therapy management

Robert A. Bechtol, Pinto, G Partha et al. · ClinicoEconomics and Outcomes Research · 2013 · 14 citations · Full text

Pharmacy, Health Administration, Pharmacoeconomics +17

Patient and Neurologist Preferences in the United States for Relapsing-Remitting Multiple Sclerosis Treatments: Findings from a Discrete Choice Experiment

Jinender Kumar, M. Janelle Cambron‐Mellott, T. Tencer et al. · Patient Preference and Adherence · 2021 · 12 citations · Full text

Life Sciences, Neurology, Neuroscience +13

Matching-Adjusted Indirect Comparison (MAIC) of Efficacy and Safety of Lisocabtagene Maraleucel (liso-cel) and Mosunetuzumab for the Treatment (Tx) of Third Line or Later (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

Loretta J. Nastoupil, Ashley Bonner, Pearl Wang et al. · Blood · 2023 · 10 citations

Pharmacy, Hematology, Immunology +17